Glucagon-like peptide 1 (GLP-1) and its analogue exendin-4 (Ex4) have displayed potent glucose homeostasis-modulating characteristics in type 2 diabetes (T2D). However, there are few reports of effectiveness in type 1 diabetes (T1D) therapy, where there is massive loss of b cells. We previously described a novel GLP-1 analogue consisting of the fusion of active GLP-1 and IgG heavy chain constant regions (GLP-1/IgG-Fc), and showed that in vivo expression of the protein, via electroporation-enhanced intramuscular plasmid-based gene transfer, normalized blood glucose levels in T2D-prone db/db mice. In the present study, GLP-1/IgG-Fc and Ex4/IgG-Fc were independently tested in multiple low-dose streptozotocin-induced T1D. Both GLP-1/ IgG-Fc and Ex4/IgG-Fc effectively reduced fed blood glucose levels in treated mice and ameliorated diabetes symptoms, where as control IgG-Fc had no effect. Treatment with GLP-1/IgG-Fc or Ex4/IgG-Fc improved glucose tolerance and increased circulating insulin and GLP-1 levels. It also significantly enhanced islet beta-cell mass, which is likely a major factor in the amelioration of diabetes. This suggests that GLP-1/IgG-Fc gene therapy may be applicable to diseases where there is either acute or chronic beta-cell injury.
Introduction
Diabetes mellitus is a major public health problem and a medical disorder characterized by varying or persistent hyperglycemia owing to an insufficiency or absolute absence of secretion or action from the insulin hormone.
1,2 Type 1 diabetes (T1D) is a complex disease that results from an autoimmune T-lymphocyte-dependent islet infiltration and destruction of islet beta-cells, 3 with consequent insulin deficiency and dependence on exogenous insulin treatment. 1, 2 A strikingly decreased functional beta-cell mass owing to apoptosis constitutes the histopathological hallmark of the disease at diagnosis. 1, 4, 5 In contrast to T1D, type 2 diabetes (T2D) is associated with peripheral insulin resistance, declined islet beta-cell compensatory capacity, beta-cell apoptosis, and eventually beta-cell failure. 6 Recently, strategies employing beta-cell growth factors to enhance functional beta-cell mass and restore insulin secretion have been proposed for the treatment of diabetes. One such promising beta-cell growth factor identified is glucagon-like peptide-1 (GLP-1). 7 In animal studies, treatment of GLP-1 and/or its potent analogue exendin-4 (Ex4) moderated onset of diabetes in both T2D 8, 9 and T1D 10,11 diabetes models. GLP-1 is an insulinotropic hormone that is secreted from intestinal L-cells in response to nutrient ingestion and promotes nutrient absorption via regulation of islet hormone secretion. 12, 13 GLP-1 binds to the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor (GPCR).
14 GLP-1R is expressed mainly by pancreatic beta-cells, and to some extent in other tissues (lungs, heart, kidney, GI tract and brain), and is coupled to the cyclic adenosine monophosphate (cAMP) second messenger pathway [14] [15] [16] involving activation of protein kinase A and the Epac family of cAMP-regulated guanine nucleotide exchange factors (cAMPGEFs). [17] [18] [19] [20] [21] Activation of other protein kinases including Akt (protein kinase B) and MAPK (mitogen-activated protein kinases 8, 17, 18 is also important in mediating GLP-1 action in promoting beta-cell growth and inhibiting apoptosis. GLP-1 enhances pancreatic islet beta-cell proliferation and inhibits beta-cell apoptosis in a glucose-dependent fashion. 7, 17, 22 GLP-1 also augments insulin secretion and lowers blood glucose in rodents as well as in humans in both T1D 22 and T2D. [23] [24] [25] However, native GLP-1 has a short circulating half-life (t 1/2 o2 min) that results mainly from rapid enzymatic inactivation by dipeptidyl-peptidase IV (DPP-IV), and/ or renal clearance. 7, 26, 27 Therefore, continuous subcutaneous infusion by pump is necessary to maintain GLP-1 action in vivo.
28,29 DPP-IV-resistant GLP-1 analogues, 30, 31 and other formulations, [32] [33] [34] appear to be promising therapeutic drug candidates for the treatment of diabetes, but these peptides require once-or twice-daily injections and/or combination therapies with oral diabetic medications.
We recently developed a novel GLP-1 fusion peptide consisting of the active human GLP-1 molecule and the murine IgG1 constant heavy-chain (IgG-Fc). 35 Plasmidbased, electroporation-enhanced intramuscular gene therapy with GLP-1/IgG-Fc improved insulin production and normalized glucose tolerance in T2D db/db mice. 35 Furthermore, this positive effect was long lasting. In the current study, using a streptozotocin (STZ)-induced beta-cell injury T1D mouse model, we investigated whether the continual expression of GLP-1/IgG-Fc could maintain sufficient beta-cell mass in order to compensate for the drug-induced beta-cell injury and prevent onset of diabetes. Our data show that intramuscular delivery of either GLP-1/IgG-Fc or Ex4/IgG-Fc plasmids in mice increased circulating active GLP-1, and markedly diminished drug-induced beta-cell loss. The treated mice were significantly protected against the onset of diabetes.
Results

GLP-1/IgG-Fc reduces blood glucose levels in STZinduced diabetic mice
A schematic representation of the secretable GLP-1/IgGFc and Ex4/IgG-Fc fusion proteins is shown in Figure 1 . The IgG-Fc fusion proteins are synthesized and secreted as bivalent molecules of B70 kDa and intramuscular injection of the encoding plasmid, followed by local electroporation, allowed expression of circulating fusions for at least 3-4 weeks. 35 As shown, five consecutive intraperitoneal injections of low dose of STZ (50 mg/kg) induced onset of diabetes in all mice after 10-12 days of injection ( Figure 2 ; n ¼ 9). However, the incidence of diabetes was significantly reduced by B50% in the STZ mice pretreated with GLP-1/IgG-Fc (Figure 2 ). The group of mice treated with Ex4/ IgG-Fc showed a similar lower rate of diabetes, when compared to the IgG-Fc-treated control mice (Figure 2 , Ex4/IgG-Fc vs IgG-Fc ¼ B45% vs 100%, n ¼ 9). It is interesting to note that the body weight among the groups did not change over the course of the study (data not shown). These results indicate that treatment of GLP-1/IgG-Fc or Ex4/IgG-Fc significantly ameliorates STZ-induced hyperglycemia in CD1 mice.
GLP-1/IgG-Fc improves IPGTT, beta-cell function and circulating insulin levels
Before initiation of the treatment (day 0), the IPGTT patterns for the three groups of mice studied were similar and there was no significant difference between the groups when the glycemic response was expressed as the area under the curve (AUC) (Figure 3a 
GLP-1/IgG-Fc increases beta-cell mass
We examined the islet beta-cell mass in the control and treated groups. As shown, STZ treatment resulted in a B75% reduction in the islet beta-cell mass when compared to untreated control mice group (Figure 4 . This confirms an amelioration of diabetes symptoms by this gene therapy. It is noticeable however that food intake and urine output measurements of GLP-1/IgG-Fc or Ex4/IgG-Fc-treated STZ mice were higher than those of untreated control mice ( Figure 6 , Po0.05, n ¼ 6-7) while water consumption was unchanged.
Discussion
GLP-1 and its analogues have been shown to regulate glucose homeostasis in animals and humans by stimulating glucose-dependent insulin synthesis and secretion, while suppressing glucagon secretion. An important feature of GLP-1 is the enhancement of islet beta-cell mass by promoting beta-cell growth and preventing beta-cell death. 36 Therefore, GLP-1 has been proposed for the treatment of diabetes. However, the short-lived nature of GLP-1 (o2 min) as a result of DPP-IV digestion and rapid renal clearance 7, 26, 27 has made peptide-based treatments challenging. Ex4, a DPP-IVresistant analogue of GLP-1, was the first approved drug in the class of incretin mimetics. Ex4 treatment involves a twice-daily injection at times in combination with oral antidiabetics. 37 However, its B50% difference in peptide sequence compared with human GLP-1 can cause immunological reactions. 38 These limitations have continued to fuel attempts to develop more potent long-acting GLP-1 analogs with minimized immunogenicity.
The novel GLP-1 analogue we developed consists of the GLP-1 peptide conjugated to murine IgG1, and is secreted as a bivalent GLP-1 molecule. 35 Conjugation to IgG-Fc can markedly increase the half-life of small protein drugs, and in some cases has provided an effective treatment option allowing weekly injections. 39, 40 GLP-1 receptors are GPCRs mostly pre-existing at the cell membrane in the form of dimers and oligomers 41, 42 and, therefore, dimeric GLP-1 peptides are expected to possess substantially increased avidity. [43] [44] [45] [46] We previously showed that in vivo expression of GLP-1/IgGFc via gene transfer significantly prevented onset of diabetes in db/db mice, 35 which is a severe T2D mouse model. This is in good agreement with our previous studies and others, showing that treatment of native GLP-1 and/or Ex4 prevents the onset of diabetes in T2D mice or rat models. GLP
In the present study, the production of either GLP-1/ IgG-Fc or Ex4/IgG-Fc following intramuscular plasmidbased gene transfer and electroporation ameliorated diabetes incidence in STZ-induced diabetes in CD1 mice. STZ is commonly used to induce diabetes and can be applied at high dosage causing rapid diabetes in most or all mouse strains, or at multiple low doses causing diabetes in only some strains, such as CD1 and C57BL/6. The beta-cell injury induced by consecutive low dose injections of STZ, as performed in this study, involves infiltration of islets by activated macrophages and some lymphocytes. [47] [48] [49] [50] This is associated with increased local and systemic release of interferon-g and tumor necrosis factor-a. It is apparent that islet cell injury and death is dependent on both the initial toxic effect of low-dose STZ, and the subsequent inflammatory response. 51 Both GLP-1/IgG-Fc and Ex4/IgG-Fc significantly ameliorated diabetes symptoms, and increased islet beta-cell mass and circulating insulin levels when compared to those of control STZ mice. Furthermore, treatment with either GLP-1/IgG-Fc or Ex4/IgG-Fc improved glucose tolerance in STZ mice, suggesting that the enhancement of beta-cell mass by GLP-1/IgG-Fc and Ex4/IgG-Fc was associated with an enhanced beta-cell function. Consistently, a reduced food intake, water consumption and urine output indicated that the metabolic conditions in these treated mice were largely improved. Our findings are in accordance with previous studies showing that GLP-1 (or Ex4) improved glucose homeostasis through enhancement of beta-cell mass, via a mechanism involving increased beta-cell neogenesis in rats treated with STZ. 9, 17 However, unlike in db/db mice, 35 where GLP-1/IgG-Fc gene therapy returned blood glucose to a normal range, this was only partially achieved in STZ mice. This is consistent with our observation from this study that treatment only partially restored islet cell mass and partially improved metabolic symptoms in the STZ model. Although T1D and T2D present similar outcomes in terms of disruption of glucose homeostasis and long-term complications, the mechanisms of development of the two are clearly different. It should be noted that although islet-cell death is related to inflammation in the STZ-induced disease, it does not appear to be an autoimmune disease, and differs considerably from autoimmune T1D in rodents and humans. In autoimmune T1D, islet cell injury is 
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clearly a T-cell-dependent process, requiring effector cells of different phenotype, including T-helper-1 cells, cytotoxic T-lymphocytes and macrophages. 52 Therefore, in autoimmune T1D it is unlikely that GLP-1 therapy alone will be sufficient to protect against disease, and additional therapy will be required to control the chronic autoimmune response. This notion is supported by the work of Ogawa et al. 10 showing that administration of both anti-T-cell antibodies and Ex4 was required to achieve clinical remission in nonobese diabetic mice. Combined therapy was characterized by normalization of glucose tolerance, improved islet histology and increased glucose-induced insulin secretion. 10 Hence, an approach that concomitantly combines regeneration of islet beta cells and specific immunoregulation is imperative for treatment of T1D. It is important to note, however, that systemic suppression of immunological responses by an anti-T-cell antibody may have adverse immunologic effects. 53 In view of this, other approaches for controlling the autoimmune response, such as DNA vaccines, are being studied in our laboratories.
In summary, this study shows that in vivo expression of the novel peptide GLP-1/IgG-Fc, and its analog Ex4/ IgG-Fc, protects against STZ-induced diabetes. This was achieved through enhancement of islet beta-cell mass, elevated circulating insulin and improved glucose tolerance. The treatment only required two intramuscular injections of GLP-1/IgG-Fc/VRnew or Ex4/IgG-Fc/ VRnew vectors, enhanced by electroporation. This approach is simple and appears safe, and could find application in diseases where there is either acute or chronic beta cell injury in the pancreas.
Materials and methods
Plasmid construction
Construction of GLP-1/IgG-Fc/VRnew and IgG-Fc/ VRnew has been described previously. 34 Briefly, fulllength GLP-1 and mouse IgG-Fc cDNAs were amplified from GLP-1/protein-coupled receptor 2.1 (PCR2.1) and IgG/VRnew plasmids, respectively, using gene-specific primers and an overlap PCR strategy, as described. 35 Construction of Ex4/IgG-Fc/VRnew was as following: full-length Ex4 cDNA was fused to mouse IgG-Fc cDNA by PCR amplification using IgG-Fc/VRnew 35 as the template. The forward primer incorporated the entire Ex4 -CCGGATATCGCCACCATGCATGGTGAA  GGAACATTTACCAGTGACTTGTCAAAACAGATGGA  AGAGGAGGCAGTGCGGTTATTTATTGAGTGGCTTA  AGAACGGAGGACCAAGTAGCGGGGCACCTCCGCC  ATCGCCCAGCGAGACCGTCACC-3 0 ) allowing onestep fusion of the two cDNAs. The reverse primer sequence (IgG-rcp) is as follows: 5 0 -CGCGGATCCCTAT CATTTACCAGGAGAGTGGGAGAGG-3 0 . The generated PCR product was subcloned into the BamHI and EcoRV sites of VRnew vector. An additional PCR amplification was carried out to insert the IgK secretion signal peptide sequence using a forward primer that included the IgK secretion signal sequence (5 0 -CCGGAT ATCGCCACCATGGAGACAGACACACTCCTGCTATG GGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTG ACCATGGTGAAGGAACATTTACCAGTGACTTG-3 0 ). IgG-rcp was used as the reverse primer. The PCR product was subcloned into the BamHI and EcoRV sites of the VRnew vector, constructed from VR1255. 54 The vector contains a CMV immediate-early enhancer-promoter, a single eukaryotic transcription unit, and minimal rabbit beta-globin polyadenylation and transcription termination sequences. 54 The VRnew vector is a derivative of the VR1255 vector, 54 which has been modified by deleting the luciferase reporter gene and adding enzyme restriction sites. To permit secretion, the Igk signal peptide sequence 35 was introduced 5 0 to the GLP-1 or Ex4 sequence by PCR. All constructed plasmids were examined by DNA sequence analysis in order to confirm the sequence accuracy.
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Animals
Seven-week-old CD1 mice (Charles River Laboratories, St Constant, QC, Canada) were housed under controlled temperature conditions and a 12-h light/12-h dark cycle in the St Michael's Hospital Animal facility with free access to food (normal rodent chow) and water except where noted. All procedures were conducted according to protocols and guidelines approved by the Canadian Council of Animal Care and the St Michael's Hospital Animal Care committee. Before intervention, body weight, feeding blood glucose, intraperitoneal glucose tolerance testing (IPGTT), water consumption, food intake and urine volume were measured and a fasting blood sample was taken from the saphenous vein for serum insulin and glucagon measurement. All animals were divided into three groups: GLP-1/IgG-Fc, Ex4/IgGFc and IgG-Fc as control.
Intramuscular gene transfer
Intramuscular plasmid DNA injections and electroporation were carried out as described previously. 35, 55 Briefly, each mouse received a total of 50 mg of DNA per treatment (25 mg in each tibialis anterior muscle). The same treatment was repeated 10 days later. After each intramuscular DNA injection, electrical current was applied locally with caliper electrodes to skin covered with conducting gel, as follows: 200 V/cm, pulse length 20 ms, eight pulses at 1-s intervals.
Diabetes induction
For inducing diabetes, 50 mg/kg body weight of STZ (Sigma Chemical Co., St Louis, MO, USA) was dissolved in cold saline immediately before use and was given intraperitoneally 7 days after the first DNA injection for 5 consecutive days. The last dose of STZ immediately followed the second DNA injection. The development of diabetes was monitored by measuring blood glucose from the tail vein. Mice were considered diabetic when sequential blood glucose measurements obtained every 3 days were X17 mmol/l (normal levels of blood glucose of non-STZ-treated mice were 7 mmol/l).
Mice were monitored for blood glucose concentrations and body weight every three days over the course of the experiment. Blood glucose was measured with an Ascensia ELITE XL glucometer and Ascensia Elite blood glucose test strips.
Intra peritoneal glucose tolerance test
For IPGTT, mice were fasted overnight for 15 h, and were given 1.5 g glucose/kg body weight (anhydrous dextrose; EMD Chemicals Inc., Gibbstown, NJ, USA) via intra-peritoneal injection. Blood was drawn from the tail vein at 0, 10, 20, 30, 60, 90 and 120 min after glucose administration.
Metabolic study
Mice were put into a metabolic cage before the first DNA injection and before killing the animals. Measurements of urine output, food intake and water consumption were measured as described previously. 56 
Radioimmunoassay
Blood samples (200 ml) were obtained from the saphenous vein (before the first DNA injections, on the day of first STZ injections and after the second DNA injections); the last blood sampling was performed before killing (1 ml) under anesthesia conditions (50 mg/kg of ketamine (Bimeda-MTC, Cambridge, ON, Canada) and xylazine hydrochloride (Bayer, Toronto, ON, Canada)) via cardiac puncture (day 20). For measurement of insulin and GLP-1 concentrations, blood samples were centrifuged and the plasma was stored at À801C for determination of above hormones using a highly sensitive insulin (Crystal Chem Inc., Downers Grove, IL, USA) and GLP-1 enzyme-linked immunosorbent assay (ELISA) kit (LINCO Research Inc., St Charles, MO, USA) designed for small sample volumes.
Pancreatic tissue preparation and immunostaining
Freshly isolated pancreata were fixed overnight in formaldehyde-acetic acid solution as described previously. 17 Each pancreas was subsequently cut into 10-12 pieces to account for the distribution of islets across the entire tissue. Following dehydration in ethanol and clearing with xylene, the pancreatic pieces were embedded in paraffin. Pancreatic sections (5 mm) were processed and immunostaining was performed as described previously. 17 Briefly, following dewaxing, dehydration and antigen retrieval, 5% normal goat serum was used to block nonspecific binding and sections were incubated overnight at 41C with guinea pig anti-insulin antibody or with rabbit anti-glucagon IgG (1:800; Dako Diagnostics, Mississauga, ON, Canada) to stain islet beta-or alpha-cells, respectively. The samples were then incubated with biotinylated mouse anti-guinea-pig IgG or rat anti-rabbit IgG (1:500, Vector Laboratories Inc., Burlingame, CA, USA) at room temperature for 2 h and subsequently treated with for 1 h with avidin/biotin/peroxidase complex (Vectastain GLP-1/IgG-Fc therapy protects against diabetes N Soltani et al Elite ABC Kit; Vector Laboratories Inc., Burlingame, CA, USA). Sections were then stained with 3,3 0 -diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories Inc., Burlingame, CA, USA) for 10 min. After DAB staining, the sections were washed with tap water and counterstained with hematoxylin.
Beta-cell mass measurement
Images were visualized using ScanScope CS and analyzed using the ImageScope program (Aperio Technologies Inc., Vista, CA, USA). Entire pancreatic tissue areas from each of the 10-12 segments of pancreas were outlined and the number of strong positive signals (Nsp) within those areas, representing insulin-or glucagonpositive cells, was determined as the function of the Positive Pixel Count Algorithm (Aperio Technologies Inc., Vista, CA, USA). This algorithm was also used to detect the number of negative signals (NTotal), which represented the total pancreatic tissue area. Total betacell mass for each pancreas was determined as the product of the total cross-sectional beta-or alpha-cell areas (Nsp) over total tissue area (NTotal) and the weight of the pancreas before fixation.
Statistical analysis
All data are presented as mean7s.e.m. Statistical analysis was performed using one-way or two-way ANOVA when indicated with the Tukey post hoc test. Po0.05 was selected for acceptance of statistical significance.
